Organon (OGN) and Shanghai Henlius Biotech said Monday the phase 3 trial of investigational Perjeta biosimilar HLX11 met its primary endpoint of total pathological complete response.
The study compared the efficacy of HLX11 with Perjeta, or pertuzumab, in locally advanced breast cancer, the companies said. Secondary endpoints are currently being analyzed.
Henlius agreed to license the global commercialization rights, except in China, for HLX11 and another biosimilar candidate to Organon in 2022, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments